Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional Femasys fertility and women’s diagnostic health products. Together with the Company’s recent market entry in Spain and the ongoing commercial launch in France, this partnership represents continued execution of Femasys’ European expansion strategy and broadens access to its innovative technologies through experienced regional partners.

“Expanding into Switzerland with OR Consulting further strengthens our European commercial platform and reflects our disciplined approach to building a multi-country footprint through experienced regional partners,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “With FemBloc launches underway in Spain and France, and Switzerland providing access to our full portfolio, including FemaSeed for fertility, we are advancing availability across Europe while executing our long-term global growth strategy.”

“Switzerland is an important and sophisticated market for women’s health innovation,” said Christophe Sarzier, Chief Executive Officer of OR Consulting. “We are excited to support the introduction of FemBloc alongside Femasys’ broader fertility and women’s health solutions. Our collaboration reflects a shared commitment to working closely with physicians, navigating complex markets effectively, and expanding access to meaningful options for patients.”

About Femasys

Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed^® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue^®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.¹

FemBloc^® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec^®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.² For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

Learn more at , or follow us on , and .

About OR Consulting

OR Consulting is a Switzerland-based medical technology consulting and distribution company with deep expertise in supporting innovative surgical and gynecologic solutions in both operating room and clinical settings. Founded and led by the same family behind Surgynal, OR Consulting draws on decades of experience in the development, commercialization, and clinical support of advanced urogynecologic and pelvic health technologies. Through this close affiliation, the company brings a strong foundation in physician education, in-procedure clinical support, and market development, and is recognized for its hands-on approach, close collaboration with healthcare providers, and commitment to introducing clinically differentiated technologies across Switzerland. More information on OR Consulting can be found at .

References

¹Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

²Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Forward-Looking Statements 

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 

David Gutierrez, Dresner Corporate Services, (312) 780-7204,

Nathan Abler, Dresner Corporate Services, (714) 742-4180,